Author:
Stowasser Michael,Ahmed Ashraf H.
Reference66 articles.
1. Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M (2011) Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 96(9):2904–2911
2. Avery TL (1984) Primary hyperaldosteronism and depression. N Z Med J 97(761):537
3. Bitran D, Shiekh M, Dowd JA, Dugan MM, Renda P (1998) Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Pharmacol Biochem Behav 60(4):879–887
4. Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, Westlake L (1992) Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305(6846):160–164
5. Buchholz K, Schorr U, Turan S, Sharma AM, Deter HC (1999) [Emotional irritability and anxiety in salt-sensitive persons at risk for essential hypertension]. Psychother Psychosom Med Psychol 49(8):284–289